{"id":507009,"date":"2020-09-15T16:44:02","date_gmt":"2020-09-15T16:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=507009"},"modified":"2020-09-15T16:44:02","modified_gmt":"2020-09-15T16:44:02","slug":"bipolar-depression-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-depression-market-size-share-trends-epidemiology-forecast-till-2030_507009.html","title":{"rendered":"Bipolar Depression Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Bipolar Depression Market, Size, Share, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Bipolar Depression Market, Size, Share, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s  &#8220;Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">Bipolar Disorder, previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed).<\/p>\n<p style=\"text-align: justify;\">The ultimate goal of&nbsp;Bipolar Depression&nbsp;treatment is to achieve as high as possible a level of psychosocial function and health-related quality of life. BD is a highly recurrent disorder and sometimes medication needs to continue even if the patient feels well.<\/p>\n<p style=\"text-align: justify;\">The treatment has two phases: the acute phase and the maintenance phase. Acute-phase treatment is focused on the management of acute mood episodes (manic, hypomanic, or depressive). Maintenance-phase treatment is focused on preventing recurrences of acute episodes. Each phase is associated with specific treatment needs, and available pharmacotherapies have shown differential effectiveness according to the illness phase.<\/p>\n<p style=\"text-align: justify;\">Most commonly mood stabilizers, antipsychotics, antidepressants, antianxiety medications, and psychotherapy is used. In the United States, only four medications are approved for acute treatment of depressive episodes in the context of bipolar disorder: Symbyax (olanzapine-fluoxetine combination), Seroquel and Seroquel XR (quetiapine), Latuda (lurasidone), and Vraylar (cariprazine). Although older medications such as lithium also have modest effects in acute bipolar depression.<\/p>\n<p style=\"text-align: justify;\">Bipolar Depression&nbsp;Market Insight<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market\" target=\"_blank\"><strong>Bipolar Depression&nbsp;market size in 7MM in 2017 was USD 762.83 million&nbsp;<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" class=\"report-heading fw-800\">Bipolar Depression&nbsp;<\/a>Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novel insights into disease<\/li>\n<li>Improvement in treatment over the years<\/li>\n<li>Increasing adherence to treatment<\/li>\n<li>Increase in awareness and advancements in the technology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Bipolar Depression&nbsp;Market Barriers<\/p>\n<ul style=\"text-align: justify;\">\n<li>Delay in diagnosis<\/li>\n<li>Unrecognized and inappropriate treatment<\/li>\n<li>Neglects of quality of life, burden, and economic issues<\/li>\n<li>Unsatisfactory design of randomized controlled trials<\/li>\n<li>Lack of Knowledge to differentiate between unipolar and bipolar depression<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-market\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-market\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><span>1. Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Executive Summary of Bipolar Depression<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Competitive Intelligence Analysis for Bipolar Depression<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. Bipolar Depression: Market Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1. Bipolar Depression Total Market Share (%) Distribution in 2017<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.2. Bipolar Depression Total Market Share (%) Distribution in 2030<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5. Bipolar Depression: Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1. Introduction<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.2. Sign and Symptoms&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.3.&nbsp;<\/span>Bipolar Depression&nbsp;<span>Pathophysiology&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.4.&nbsp;<\/span>Bipolar Depression&nbsp;<span>Risk Factors&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.&nbsp;<\/span>Bipolar Depression&nbsp;<span>Diagnosis&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>6. Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7. Bipolar Depression Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.1. Epidemiology Key Findings<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.2. Assumptions and Rationale: 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.3. Epidemiology Scenario: 7MM<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.3.1. Bipolar Depression Epidemiology Scenario in the 7MM (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.4. United States&nbsp;<\/span>Bipolar Depression&nbsp;<span>Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.4.1. Bipolar Depression Epidemiology Scenario in the United States (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.5. EU-5 Country-wise Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.1. Germany&nbsp;<\/span>Bipolar Depression&nbsp;<span>Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.1.1. Bipolar Depression Epidemiology Scenario in Germany (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.2. France&nbsp;<\/span>Bipolar Depression&nbsp;<span>Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.2.1. Bipolar Depression Epidemiology Scenario in France (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.3. Italy&nbsp;<\/span>Bipolar Depression&nbsp;<span>Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.3.1. Bipolar Depression Epidemiology Scenario in Italy (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.4. Spain&nbsp;<\/span>Bipolar Depression&nbsp;<span>Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.4.1. Bipolar Depression Epidemiology Scenario in Spain (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.5. United Kingdom&nbsp;<\/span>Bipolar Depression&nbsp;<span>Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.5.1. Bipolar Depression Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.6. Japan&nbsp;<\/span>Bipolar Depression&nbsp;<span>Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.6.1. Bipolar Depression Epidemiology Scenario in Japan (2017-2030)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.1. Bipolar Depression Treatment and Management<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.2. Bipolar Depression Treatment Algorithm&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9.&nbsp;<\/span><span>Bipolar Depression&nbsp;<\/span><span>Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. Key Endpoints of Bipolar Depression Treatment<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11.&nbsp;<\/span><span>Bipolar Depression&nbsp;<\/span><span>Marketed Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.1. List of Marketed Products in the 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.2. Drug Name: Company Name<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>11.2.1. Product Description<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>11.2.2. Regulatory Milestones<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>11.2.3. Other Developmental Activities<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>11.2.4. Pivotal Clinical Trials<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>11.2.5. Summary of Pivotal Clinical Trial<\/span><\/p>\n<p style=\"text-align: justify;\"><span>List to be continued in report<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12.&nbsp;<\/span><span>Bipolar Depression&nbsp;<\/span><span>Emerging Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.1. Key Cross<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.2. Drug Name: Company Name<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>12.2.1. Product Description<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>12.2.2. Other Developmental Activities<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>12.2.3. Clinical Development<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>12.2.4. Safety and Efficacy<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>12.2.5. Product Profile<\/span><\/p>\n<p style=\"text-align: justify;\"><span>List to be continued in report<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13. Bipolar Depression: Seven Major Market Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1. Key Findings<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.2. Bipolar Depression Market Size in 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.3. Bipolar Depression Market Size by Therapies in the 7MM<\/span><\/p>\n<p style=\"text-align: justify;\"><span>14. Attribute analysis<\/span><\/p>\n<p style=\"text-align: justify;\"><span>15. 7MM: Market Outlook<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.1. United States:&nbsp;<\/span>Bipolar Depression&nbsp;<span>Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.1.1. Bipolar Depression Total Market Size in the United States<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.1.2. Bipolar Depression Market Size by Therapies in the United States<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.2. EU-5 countries: Market Size and Outlook<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.3. Germany&nbsp;<\/span>Bipolar Depression&nbsp;<span>Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.3.1. Bipolar Depression Total Market Size in Germany<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.3.2. Bipolar Depression Market Size by Therapies in Germany<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.4. France&nbsp;<\/span>Bipolar Depression&nbsp;<span>Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.4.1. Bipolar Depression Total Market Size in France<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.4.2. Bipolar Depression Market Size by Therapies in France<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.5. Italy&nbsp;<\/span>Bipolar Depression&nbsp;<span>Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.5.1. Bipolar Depression Total Market Size in Italy<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.5.2. Bipolar Depression Market Size by Therapies in Italy<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.6. Spain&nbsp;<\/span>Bipolar Depression&nbsp;<span>Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.6.1. Bipolar Depression Total Market Size in Spain<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.6.2. Bipolar Depression Market Size by Therapies in Spain<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.7. United Kingdom&nbsp;<\/span>Bipolar Depression&nbsp;<span>Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.7.1. Bipolar Depression Total Market Size in the United Kingdom<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.7.2. Bipolar Depression Market Size by Therapies in the United Kingdom<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.8. Japan&nbsp;<\/span>Bipolar Depression&nbsp;<span>Market Outlook<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.8.1. Japan Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.8.2. Bipolar Depression Total Market Size in Japan<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.8.3. Bipolar Depression Market Size by Therapies in Japan<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16. Access and Reimbursement Overview of Bipolar Depression<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. KOL Views<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18.&nbsp;<\/span><span>Bipolar Depression&nbsp;<\/span><span>Market Drivers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19.&nbsp;<\/span><span>Bipolar Depression&nbsp;<\/span><span>Market&nbsp;<\/span><span>Barriers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>20.1. Bibliography<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>20.2.&nbsp;<\/span>Bipolar Depression&nbsp;<span>Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21. DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>22. Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>23. About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bipolar-depression-market-size-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bipolar-depression-market-size-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-depression-market-size-share-trends-epidemiology-forecast-till-2030_507009.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-507009","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/507009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=507009"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/507009\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=507009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=507009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=507009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}